You will be given a definition of a task first, then some input of the task.
In this task, you are given an abstract of article. Your task is to generate title for this article. Preferred titles are under thirty words.

Background In a phase 1 trial, axicabtagene ciloleucel (axicel), an autologous antiCD19 chimeric antigen receptor (CAR) Tcell therapy, showed efficacy in patients with refractory large Bcell lymphoma after the failure of conventional therapy. Methods In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large Bcell lymphoma, primary mediastinal Bcell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2106 antiCD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of lowdose cyclophosphamide and fludarabine. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Secondary end points included overall survival, safety, and biomarker assessments. Results Among the 111 patients who were enrolled, axicel was successfully manufactured for 110 (99%) and administered to 101 (91%). The objective response rate was 82%, and the complete response rate was 54%.With a median followup of 15.4 months, 42% of the patients continued to have a response, with 40% continuing to have a complete response. The overall rate of survival at 18 months was 52%. The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 13% and 28% of the patients, respectively. Three of the patients died during treatment. Higher CAR Tcell levels in blood were associated with response. Conclusions In this multicenter study, patients with refractory large Bcell lymphoma who received CAR Tcell therapy with axicel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration Program; ZUMA1 ClinicalTrials.gov number, NCT02348216.)
Output:
Axicabtagene Ciloleucel CAR TCell Therapy in Refractory Large BCell Lymphoma